Cosmo Pharmaceuticals N.V.
CMOPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $870 | $1,057 | $1,208 | $765 |
| - Cash | $51 | $44 | $55 | $50 |
| + Debt | $3 | $2 | $1 | $2 |
| Enterprise Value | $822 | $1,015 | $1,155 | $717 |
| Revenue | $52 | $131 | $136 | $49 |
| % Growth | -60.4% | -4.2% | 177.4% | – |
| Gross Profit | $26 | $134 | $113 | $29 |
| % Margin | 50.6% | 102.5% | 83% | 58.3% |
| EBITDA | $5 | $71 | $94 | $6 |
| % Margin | 9.4% | 54.7% | 69.2% | 11.5% |
| Net Income | -$2 | $57 | $76 | -$6 |
| % Margin | -3.9% | 43.8% | 55.8% | -13.1% |
| EPS Diluted | -0.13 | 3.43 | 4.71 | -0.4 |
| % Growth | -103.8% | -27.2% | 1,277.5% | – |
| Operating Cash Flow | $1 | $63 | $99 | $18 |
| Capital Expenditures | -$3 | -$4 | -$1 | -$2 |
| Free Cash Flow | -$2 | $59 | $98 | $16 |